CN116324412A - 抗原组合用于检测肺癌中的自身抗体的用途 - Google Patents

抗原组合用于检测肺癌中的自身抗体的用途 Download PDF

Info

Publication number
CN116324412A
CN116324412A CN202180062774.5A CN202180062774A CN116324412A CN 116324412 A CN116324412 A CN 116324412A CN 202180062774 A CN202180062774 A CN 202180062774A CN 116324412 A CN116324412 A CN 116324412A
Authority
CN
China
Prior art keywords
ssx1
tumor marker
hud
sox2
koc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062774.5A
Other languages
English (en)
Chinese (zh)
Inventor
安德烈亚·默里
贾里德·艾伦
菲利普·冈宁
伊莎贝尔·麦克唐纳
塞利娜·帕尔西-科瓦尔斯卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Freenome Ltd
Original Assignee
Oncimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010677754.6A external-priority patent/CN113933509A/zh
Priority claimed from GB2017434.8A external-priority patent/GB2600701A/en
Application filed by Oncimmune Ltd filed Critical Oncimmune Ltd
Publication of CN116324412A publication Critical patent/CN116324412A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180062774.5A 2020-07-14 2021-07-14 抗原组合用于检测肺癌中的自身抗体的用途 Pending CN116324412A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010677754.6A CN113933509A (zh) 2020-07-14 2020-07-14 抗体测定
CN202010677754.6 2020-07-14
GB2017434.8 2020-11-04
GB2017434.8A GB2600701A (en) 2020-11-04 2020-11-04 Antibody assay
PCT/EP2021/069668 WO2022013321A2 (en) 2020-07-14 2021-07-14 Antibody assay

Publications (1)

Publication Number Publication Date
CN116324412A true CN116324412A (zh) 2023-06-23

Family

ID=76971915

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062774.5A Pending CN116324412A (zh) 2020-07-14 2021-07-14 抗原组合用于检测肺癌中的自身抗体的用途

Country Status (6)

Country Link
US (1) US20230266331A1 (enExample)
EP (1) EP4182693A2 (enExample)
JP (1) JP7744641B2 (enExample)
KR (1) KR20230068378A (enExample)
CN (1) CN116324412A (enExample)
WO (1) WO2022013321A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024197052A1 (en) * 2023-03-20 2024-09-26 Rush University Medical Center Circulating autoantibody biomarkers to supplement lung cancer screening

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB2424273B (en) 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
US9347945B2 (en) * 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20100204055A1 (en) * 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
CN103383395B (zh) * 2013-07-10 2015-09-09 杭州市第一人民医院 一种用于检测肺癌自身抗体的液相芯片试剂盒
CN103869086B (zh) * 2014-04-14 2016-02-17 杭州凯保罗生物科技有限公司 一种血清自身抗体检测试剂盒
GB201411060D0 (en) * 2014-06-20 2014-08-06 Oncimmune Ltd Improved immunoassay method
CN110716050A (zh) * 2019-11-13 2020-01-21 基因科技（上海）股份有限公司 抗原组合在制备用于肺癌相关自身抗体检测的试剂盒中的用途以及相应的试剂盒和检测方法

Also Published As

Publication number Publication date
JP7744641B2 (ja) 2025-09-26
KR20230068378A (ko) 2023-05-17
WO2022013321A2 (en) 2022-01-20
EP4182693A2 (en) 2023-05-24
JP2023533815A (ja) 2023-08-04
WO2022013321A3 (en) 2022-03-10
US20230266331A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CN111337678B (zh) 与肿瘤免疫治疗效果相关的生物标志物及其应用
CN108107218B (zh) 抗体测定
US20110201517A1 (en) Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
CN106662586B (zh) 改进的免疫测定方法
US20100204055A1 (en) Autoantibody detection systems and methods
US20160299145A1 (en) Methods and Kits for Detecting Prostate Cancer Biomarkers
US20130225442A1 (en) Lung Cancer Tests
WO2010096674A2 (en) A+ biomarker assays
AU2010252907B2 (en) Methods for the diagnosis or prognosis of colorectal cancer
KR20120098992A (ko) 암의 검출을 위한 방법 및 시스템
US20210318316A1 (en) Lung cancer protein epitomic biomarkers
AU2020270071A1 (en) Non-HLA markers of transplant rejection
CN115877006B (zh) 卵巢癌相关的生物标志物及其应用
JP7744641B2 (ja) 肺癌における自己抗体を検出するための抗原の組合せの使用
CN103257227B (zh) 改进的免疫测定方法
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
CN113933509A (zh) 抗体测定
GB2600701A (en) Antibody assay
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
TW201928351A (zh) 抗體測定

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Britain

Address after: Nottingham, England

Applicant after: Furim Co.,Ltd.

Address before: Nottingham, England

Applicant before: ONCIMMUNE Ltd.

Country or region before: Britain

CB02 Change of applicant information